%0 Journal Article
%T 沙库巴曲缬沙坦治疗心房颤动合并心力衰竭的研究进展<br>Research Progress of Sacubitril/Valsartan in the Treatment of Patients with Atrial Fibrillation Complicated with Heart Failure
%A 李洋
%A 褚红硕
%A 徐勤成
%A 田飞飞
%J Journal of Clinical Personalized Medicine
%P 542-549
%@ 2334-3443
%D 2025
%I Hans Publishing
%R 10.12677/jcpm.2025.41079
%X 心房颤动和心力衰竭是两种常见的心血管疾病&#65292;两者具有很多相同的危险因素&#65292;常合并存在并相互促进&#65292;且房颤合并心衰时较任一疾病预后更差。本文旨在总结近年来沙库巴曲缬沙坦在治疗房颤合并心衰方面的研究进展&#65292;探讨沙库巴曲缬沙坦能否成为治疗房颤合并心衰的一线用药。<br>Atrial fibrillation and heart failure are two common cardiovascular diseases. They have many of the same risk factors, often coexist and promote each other, and the prognosis of atrial fibrillation combined with heart failure is worse than either disease. This article aims to summarize the research progress of sacubitril/valsartan in the treatment of atrial fibrillation complicated with heart failure in recent years, and to explore whether sacubitril/valsartan can be the first-line drug for the treatment of atrial fibrillation complicated with heart failure.
%K 沙库巴曲缬沙坦&#65292
%K 心房颤动&#65292
%K 心力衰竭<br>Sacubitril/Valsartan
%K Atrial Fibrillation
%K Heart Failure
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=107795